These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27994752)

  • 1. Identification of an Orally Efficacious GPR40/FFAR1 Receptor Agonist.
    Agarwal S; Sasane S; Deshmukh P; Rami B; Bandyopadhyay D; Giri P; Giri S; Jain M; Desai RC
    ACS Med Chem Lett; 2016 Dec; 7(12):1134-1138. PubMed ID: 27994752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel free fatty acid receptor 1 (GPR40/FFAR1) agonist, MR1704, enhances glucose-dependent insulin secretion and improves glucose homeostasis in rats.
    Tsuda N; Kawaji A; Sato T; Takagi M; Higashi C; Kato Y; Ogawa K; Naba H; Ohkouchi M; Nakamura M; Hosaka Y; Sakaki J
    Pharmacol Res Perspect; 2017 Aug; 5(4):. PubMed ID: 28805970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Updates on Free Fatty Acid Receptor 1 (GPR-40) Agonists for the Treatment of Type 2 Diabetes Mellitus.
    Rani L; Grewal AS; Sharma N; Singh S
    Mini Rev Med Chem; 2021; 21(4):426-470. PubMed ID: 33100202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
    Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
    Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist.
    Negoro N; Sasaki S; Mikami S; Ito M; Suzuki M; Tsujihata Y; Ito R; Harada A; Takeuchi K; Suzuki N; Miyazaki J; Santou T; Odani T; Kanzaki N; Funami M; Tanaka T; Kogame A; Matsunaga S; Yasuma T; Momose Y
    ACS Med Chem Lett; 2010 Sep; 1(6):290-4. PubMed ID: 24900210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of GPR40/FFAR1 does not induce diabetes even under insulin resistance condition.
    Matsuda-Nagasumi K; Takami-Esaki R; Iwachidow K; Yasuhara Y; Tanaka H; Ogi K; Nakata M; Yano T; Hinuma S; Taketomi S; Odaka H; Kaisho Y
    Diabetes Obes Metab; 2013 Jun; 15(6):538-45. PubMed ID: 23331570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of DS-1558: A Potent and Orally Bioavailable GPR40 Agonist.
    Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Hirouchi M; Yoneyama T; Ito S; Toda N
    ACS Med Chem Lett; 2015 Mar; 6(3):266-70. PubMed ID: 25815144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CPL207280, a Novel G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1-Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals.
    Bazydlo-Guzenda K; Buda P; Matloka M; Mach M; Stelmach F; Dzida R; Smuga D; Hucz-Kalitowska J; Teska-Kaminska M; Vialichka V; Dubiel K; Kaminska B; Wieczorek M; Pieczykolan J
    Mol Pharmacol; 2021 Oct; 100(4):335-347. PubMed ID: 34349026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic GPR40/FFAR1 agonists: An exhaustive survey on the most recent chemical classes and their structure-activity relationships.
    Paul A; Nahar S; Nahata P; Sarkar A; Maji A; Samanta A; Karmakar S; Maity TK
    Eur J Med Chem; 2024 Jan; 264():115990. PubMed ID: 38039791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of orally effective and safe GPR40 agonists by incorporating a chiral, rigid and polar sulfoxide into β-position to the carboxylic acid.
    Chen C; Guo SM; Sun Y; Li H; Hu N; Yao K; Ni H; Xia Z; Xu B; Xie X; Long YQ
    Eur J Med Chem; 2023 May; 251():115267. PubMed ID: 36933395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel GPR40 agonists.
    Jiang XW; Jiang BE; Liu H; Liu ZT; Hu LL; Liu M; Lu W; Zhang HK
    Eur J Med Chem; 2018 Oct; 158():123-133. PubMed ID: 30212763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The G-Protein-Coupled Long-Chain Fatty Acid Receptor GPR40 and Glucose Metabolism.
    Tomita T; Hosoda K; Fujikura J; Inagaki N; Nakao K
    Front Endocrinol (Lausanne); 2014; 5():152. PubMed ID: 25309513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) by free fatty acid receptor 1 (FFAR1/GPR40) protects from palmitate-induced beta cell death, but plays no role in insulin secretion.
    Panse M; Gerst F; Kaiser G; Teutsch CA; Dölker R; Wagner R; Häring HU; Ullrich S
    Cell Physiol Biochem; 2015; 35(4):1537-45. PubMed ID: 25792236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute administration of GPR40 receptor agonist potentiates glucose-stimulated insulin secretion in vivo in the rat.
    Doshi LS; Brahma MK; Sayyed SG; Dixit AV; Chandak PG; Pamidiboina V; Motiwala HF; Sharma SD; Nemmani KV
    Metabolism; 2009 Mar; 58(3):333-43. PubMed ID: 19217448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A FFAR1 full agonist restores islet function in models of impaired glucose-stimulated insulin secretion and diabetic non-human primates.
    Rady B; Liu J; Huang H; Bakaj I; Qi J; Lee SP; Martin T; Norquay L; Player M; Pocai A
    Front Endocrinol (Lausanne); 2022; 13():1061688. PubMed ID: 36482991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of brain n-3 fatty acids-GPR40/FFAR1 signaling in pain].
    Nakamoto K; Tokuyama S
    Nihon Yakurigaku Zasshi; 2018; 151(1):21-26. PubMed ID: 29321392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists.
    Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Toda N
    Bioorg Med Chem Lett; 2014 Jul; 24(13):2949-53. PubMed ID: 24835985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SCO-267, a GPR40 Full Agonist, Improves Glycemic and Body Weight Control in Rat Models of Diabetes and Obesity.
    Ueno H; Ito R; Abe SI; Ookawara M; Miyashita H; Ogino H; Miyamoto Y; Yoshihara T; Kobayashi A; Tsujihata Y; Takeuchi K; Watanabe M; Yamada Y; Maekawa T; Nishigaki N; Moritoh Y
    J Pharmacol Exp Ther; 2019 Aug; 370(2):172-181. PubMed ID: 31182471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR40 agonists with improved pharmacokinetic and safety profiles.
    Guo B; Guo S; Huang J; Li J; Li J; Chen Q; Zhou X; Xie X; Yang Y
    Bioorg Med Chem; 2018 Dec; 26(22):5780-5791. PubMed ID: 30392954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GPR40 full agonism exerts feeding suppression and weight loss through afferent vagal nerve.
    Ueno H; Ito R; Abe SI; Ogino H; Maruyama M; Miyashita H; Miyamoto Y; Moritoh Y; Tsujihata Y; Takeuchi K; Nishigaki N
    PLoS One; 2019; 14(9):e0222653. PubMed ID: 31525244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.